{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:57:50Z","timestamp":1771930670150,"version":"3.50.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Denosumab and romosozumab are two biological agents with potential immunomodulatory effects commonly used to treat osteoporosis. This study aimed to compare the safety of these two drugs using the FDA Adverse Event Reporting System (FAERS) with a focus on immune-related adverse reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data for the second quarter of 2019 (approval date for romosozumab) and the second quarter of 2025 were extracted from the FAERS database. After standardized data cleaning, disproportionality analysis and the Bayesian approach were applied to detect safety signals for the two biological agents simultaneously.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After data extraction and cleaning, 38,784 and 10,007 reports were obtained for denosumab and romosozumab, respectively. Denosumab was associated with long-term cumulative risk and showed strong signals in musculoskeletal and metabolic disorders. In contrast, romosozumab demonstrated an acute and severe cardiovascular risk with strong signals for coronary artery disease and heart failure. Regarding immune-related events, denosumab was associated with osteoimmune complications such as noninfectious gingivitis, whereas the immune-related risk of romosozumab was limited to minor injection-site reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Research based on FAERS revealed distinct differences in the safety profiles of denosumab and romosozumab. Clinical decision makers should deepen their understanding of these features to advance personalized therapy and improve medication safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1766601","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:45:51Z","timestamp":1770273951000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative safety of denosumab and romosozumab in osteoporosis: an analysis based on the FDA adverse event reporting system database"],"prefix":"10.3389","volume":"13","author":[{"given":"Jian","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Orthopedics, The Second Affiliated Hospital of Anhui Medical University","place":["Hefei, Anhui Province, China"]},{"name":"Institute of Orthopedics, Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University","place":["Hefei, Anhui Province, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciren","family":"Lunzhu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Shannan City People\u2019s Hospital","place":["Shannan, Xizang Autonomous Region, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Plastic and Cosmetic Burns, Anhui No.2 Provincial People\u2019s Hospital","place":["Hefei, Anhui Province, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, The Second Affiliated Hospital of Anhui Medical University","place":["Hefei, Anhui Province, China"]},{"name":"Institute of Orthopedics, Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University","place":["Hefei, Anhui Province, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/s0140-6736(18)32112-3","article-title":"Osteoporosis","volume":"393","author":"Compston","year":"2019","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s00198-015-3093-2","article-title":"Projection of osteoporosis-related fractures and costs in China: 2010-2050","volume":"26","author":"Si","year":"2015","journal-title":"Osteoporos Int"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological Management of Osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1210\/er.2007-0014","article-title":"Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease","volume":"29","author":"Kearns","year":"2008","journal-title":"Endocr Rev"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00198-011-1755-2","article-title":"Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?","volume":"23","author":"Watts","year":"2012","journal-title":"Osteoporos Int"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1579101","DOI":"10.3389\/fendo.2025.1579101","article-title":"The efficacy and safety of denosumab, risedronate, alendronate and teriparatide to treat male osteoporosis: a systematic review and bayesian network meta-analysis","volume":"16","author":"Chai","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"E478","DOI":"10.1073\/pnas.1409857112","article-title":"Osteocytes mediate the anabolic actions of canonical Wnt\/\u03b2-catenin signaling in bone","volume":"112","author":"Tu","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1161\/ATVBAHA.116.308723","article-title":"Wnt signaling pathway inhibitor sclerostin inhibits angiotensin II-induced aortic aneurysm and atherosclerosis","volume":"37","author":"Krishna","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref12","volume-title":"FDA adverse event reporting system (FAERS) public dashboard [internet]","year":"2018"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/pds.3805","article-title":"Standardisation of the FAERS database: a systematic approach to manually recoding drug name variants","volume":"24","author":"Wong","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"ref15","volume-title":"Guidelines on the use of statistical signal detection methods in eudravigilance data analysis systems","year":"2008"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"ref17","volume-title":"Immunotoxicity associated with immune checkpoint inhibitors: Guidance for industry","year":"2022"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"116586","DOI":"10.1016\/j.bone.2019.115121","article-title":"Denosumab or romosozumab therapy and risk of cardiovascular events: a systematic review and meta-analysis","volume":"166","author":"Lv","year":"2023","journal-title":"Bone"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta24290","article-title":"Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation","volume":"24","author":"Davis","year":"2020","journal-title":"Health Technol Assess"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11657-019-0608-z","article-title":"Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension","volume":"14","author":"Miyauchi","year":"2019","journal-title":"Arch Osteoporos"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation","volume":"103","author":"Anastasilakis","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/nejmcp1513724","article-title":"Postmenopausal osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/nejmoa1808082","article-title":"Fracture prevention with zoledronate in older women with osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00198-012-2052-4","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial","volume":"24","author":"McClung","year":"2013","journal-title":"Osteoporos Int"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00198-025-07707-7","article-title":"Efficacy and safety of romosozumab in patients with chronic kidney disease and osteoporosis: a narrative review","volume":"36","author":"Abdalbary","year":"2025","journal-title":"Osteoporos Int"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inf J"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.13948","article-title":"Emerging opportunities to harness real world data: an introduction to data sources, concepts, and applications","volume":"22","author":"O'Leary","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s00223-016-0126-6","article-title":"Sclerostin inhibition in the management of osteoporosis","volume":"98","author":"Appelman-Dijkstra","year":"2016","journal-title":"Calcif Tissue Int"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1766601\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:57:16Z","timestamp":1771927036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1766601\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":32,"alternative-id":["10.3389\/fmed.2026.1766601"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1766601","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"article-number":"1766601"}}